Table 1:
Patient characteristics (N = 339).
| Variable | Values |
|---|---|
| KTR age (years), mean (SD) | 61.6 (9.9) |
| Male, n (%) | 250 (73.7) |
| Time after transplantation (months), median (IQR) | 72.3 (27.3–141.8) |
| Pre-KT type 2 DM, n (%) | 134 (39.5) |
| Pre-KT type 2 DM duration (years), median (IQR) | 16.9 (12.2–23.0) |
| PTDM, n (%) | 205 (60.5) |
| PTDM duration (months), median (IQR) | 47.5 (17.1–104.5) |
| Pre-KT coronary disease, n (%) | 62 (18.3) |
| Pre-KT stroke, n (%) | 21 (6.2) |
| Pre-KT peripheral vascular disease, n (%) | 34 (10) |
| Immunosuppression, n (%) | |
| Tacrolimus | 298 (87.9) |
| Cyclosporine | 10 (2.9) |
| Mycophenolic acid | 270 (79.6) |
| Everolimus | 31 (9.1) |
| Sirolimus | 32 (9.4) |
| Prednisone | 194 (57.2) |
| Antidiabetic agents, n (%) | |
| Long-acting insulin | 172 (50.7) |
| Short-acting insulin | 94 (26.8) |
| Metformin | 112 (33.0) |
| DPP-4i | 124 (36.6) |
| GLP-1 RA | 44 (13.0) |
| Others | 42 (12.4) |
| SGLT2i, n (%) | |
| Canaglifozin | 64 (18.9) |
| Empaglifozin | 193 (56,9) |
| Dapaglifozin | 81 (23.9) |
| Ertuglifozin | 1 (0.3) |
DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist.